Special Issue

Recent Advances in Malaria Vaccine Development

Message from the Guest Editors

Infections caused by malaria parasites are a major burden to global human health. As one of the deadliest parasitic diseases, malaria continues to cause significant morbidity and mortality, with an estimated 241 million clinical cases and over 0.6 million deaths reported in 2021*. Increasing resistance to currently deployed anti-malarial drugs continues to be a major concern in the fight against the disease. While Plasmodium falciparum causes the majority of malariarelated mortality, safe and efficacious vaccines for both P. falciparum and P. vivax are needed as cost-effective tools for the prevention and elimination of malaria globally. Importantly, in addition to the world's first and only vaccine recommended for falciparum malaria prevention in children (RTS, S/ASO1), multiple vaccines against malaria that provide high efficacy and meet the malaria vaccine supply capacity will be necessary. This Special Issue of Vaccines aims to showcase new developments in both falciparum and vivax malaria vaccines. We look forward to your contributions, including original research and reviews, for this Special Issue. *WHO World Malaria Report 2022

Guest Editors

Dr. Ahmad Rushdi Shakri

Division of Infectious Disease and International Medicine, Department of Internal Medicine, University of South Florida, 3720 Spectrum Blvd, Tampa, FL 33612, USA

Dr. Dipak Raj

Division of Infectious Disease and International Medicine, Department of Internal Medicine, University of South Florida, 3720 Spectrum Blvd, Tampa, FL 33612, USA

Deadline for manuscript submissions

closed (30 June 2025)



an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



mdpi.com/si/174789

Vaccines **Editorial Office** MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 vaccines@mdpi.com

mdpi.com/journal/ vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

